225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
EBITDA before special items falls 1.3 percent to € 4.41 billion
Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024
The company has posted net profit of Rs. 4,121.55 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.357.7 crores for the Financial Year ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
